Korro Bio, Inc.
KRRO Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$12.02
KIRA · Stoqly’s AI analyst, in plain words
- Korro Bio, Inc. had $6.4M of revenue in fiscal 2025, up 181.5% on the year before. Over five years, revenue changed −29.6% a year on average.
- Its operating margin was −1,906.4%, up 2,140.7 pts: of every 100 in sales, about −1,906 is left after running the business.
- Korro Bio, Inc. lost $117M in fiscal 2025.
- Free cash flow was −$79.1M in fiscal 2025, −1,237.2% of revenue.
Market cap
$212M
P/E
—
Revenue
$6.4M
Net income
−$117M
Free cash flow
−$79.1M
Operating margin
−1,906.4%
Korro Bio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+181.5%
Yes. Sales grew 181.5% last year.
Does it make a profit?
−1,834.5%
No. It lost money last year.
Does profit turn into cash?
−1,237.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Korro Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Korro Bio, Inc.
- CIK
- 0001703647
Korro Bio, Inc. · KRRO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $14.1M | $0.0M | $0.0M | $2.3M | $6.4M |
| Revenue growth | −62.0% | −100.0% | — | — | 181.5% |
| Net interest income | — | −$0.1M | $0.0M | — | — |
| Operating margin | −597.3% | — | — | −4,047.1% | −1,906.4% |
| Net income | −$84.7M | −$58.0M | −$81.2M | −$83.6M | −$117M |
| Net margin | −602.0% | — | — | −3,680.4% | −1,834.5% |
| Diluted EPS | −$2.47 | −$227.42 | −$53.08 | −$9.37 | −$12.48 |
| Cash | |||||
| Cash from operations | −$76.1M | −$53.6M | −$67.3M | −$60.1M | −$78.6M |
| Capital expenditure | $2.9M | $5.1M | $7.8M | $17.9M | $0.5M |
| Free cash flow | −$79.0M | −$58.8M | −$75.1M | −$78.0M | −$79.1M |
| FCF margin | −561.4% | — | — | −3,433.6% | −1,237.2% |
| Share count change | 6.5% | −99.3% | 499.3% | 483.3% | 5.3% |
| Debt and strength | |||||
| Cash and short-term investments | $131M | $55.2M | $166M | $126M | $75.2M |
| Debt incl. finance leases | $0.8M | $10.0M | — | — | — |
| Shareholders' equity | −$42.2M | −$99.0M | $170M | $160M | $51.4M |
| Current ratio | 11.8x | 6.6x | 8.9x | 8.8x | 6.9x |
| Interest coverage | −110.0x | −61.4x | — | — | — |
| Returns and quality | |||||
| Return on equity | −112.7% | — | −229.0% | −50.6% | −110.7% |
| Return on tangible equity | — | — | −47.8% | −52.1% | −228.0% |
| Piotroski F-score | 2 | 2 | 3 | 2 | 2 |
| Altman Z'' | −2.7 | −17.2 | 2.7 | −0.6 | −13.3 |
Insiders bought, 12 months
$3.3M
3 insiders
Insiders sold, 12 months
$5.7M
6 insiders
Of sales under plans
92%
$5.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Korro Bio, Inc. · KRRO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.02 a share, the company is worth $212M.
Source: SEC EDGAR XBRL filings (CIK 0001703647). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.